Abstract: Interleukin-23(IL-23) is a natural cytokine involved in inflammation and immune response. Risankizumab is a humanized anti-IL-23 monoclonal antibody, which can bind with high affinity to IL-23 p19 subunit, thereby inhibiting the inflammatory response. It was approved for the treatment of patients with moderate-to-severe plaque psoriasis by the U.S. Food and Drug Administration on April 23, 2019. The most common treatment-related adverse events include upper respiratory infections, headache, tiredness, injection site reactions, and fungal infections, and patients are generally well tolerated. This paper introduced risankizumab from the aspects of mechanism, pharmacokinetics, clinical application and adverse reactions.